{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"42"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"}],"units":"Participants"}],"description":"Number of Patient achieving complete remissions (CR1) at 60 days after ASCT","groups":[{"description":"Melphalan 100mg/m2/day iv days -2 and -1\n\nMelphalan: High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive melphalan at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day on days -2 and -1, with the ASCT at day 0.","id":"OG000","title":"Arm A (Mel)"},{"description":"Melphalan 100mg/m2/day iv days -2 and -1 Bendamustine 200mg/m2/day iv days -4 and -3\n\nMelphalan: High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive melphalan at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day on days -2 and -1, with the ASCT at day 0.\n\nBendamustine: High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive bendamustine at a total dose of 400mg/m2, divided in two doses of 200mg/m2/day on days -4 and -3. Melphalan is given at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day, each on days -2 and -1, with the ASCT at day 0.","id":"OG001","title":"Arm B (BenMel)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Response rates were assessed according to the International Myeloma Working Group (IMWG). Bone marrow (BM) was assessed by cytomorphology, histopathology with immunohistochemistry, and immunophenotyping by multiparameter flow cytometry (MFC) for detection of measurable residual disease (MRD). MRD negativity was defined by less than 10-5 aberrant plasma cells after measuring at least 1000000 nucleated cells.","reportingStatus":"POSTED","timeFrame":"60 days","title":"Complete Remission Rate","type":"PRIMARY","unitOfMeasure":"Participants"}